Compare Amphastar Pharmaceuticals Inc (AMPH) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Snap Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Snap Inc trades at $4.66 (market cap $7.87B). The key difference: Snap Inc is far larger — about 9.5× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | SNAP | |
|---|---|---|
Market Cap | $826.08M | $7.87B |
Sector | Health | Media |
52-Week High | $30.81 | $10.35 |
52-Week Low | $16.87 | $3.93 |
Enterprise Value | $1.22B | $9.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Snap Inc. (SNAP) trades at $4.68, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported revenue of $5.93 billion in 2025, with a net loss narrowing to -$460 million, showing improved profitability trends. Recent news highlights the launch of SPECS AR glasses priced at $2,195, which has drawn investor skepticism over pricing and demand.
The outlook remains cautious; while Snap has beaten EPS estimates in recent quarters and holds a consensus price target of $6.92, high debt levels and persistent net losses pose risks. Investor sentiment is mixed amid competitive pressures and regulatory scrutiny, requiring careful evaluation of growth initiatives against financial sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
